Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 18/20 | 0.39 |
| ▸ | PLK2 | Q9NYY3 | 2/20 | 0.36 |
| ▸ | PLK3 | Q9H4B4 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.36 |
| ▸ | TTK | P33981 | 3/20 | 0.35 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.34 |
| ▸ | PIP4K2B | P78356 | 1/20 | 0.34 |
| ▸ | PLK4 | O00444 | 1/20 | 0.33 |
| ▸ | GAK | O14976 | 1/20 | 0.33 |
| ▸ | STK33 | Q9BYT3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4107802 | 0.99 | PLK1 (0.39) | PLK1PLK2PLK3BRD4BRDT | |
| SCHEMBL3543736 | 0.88 | PLK1 (0.40) | PLK1PLK2PLK3BRD4BRDT | |
| SCHEMBL523699 | 0.86 | PLK1 (0.41) | PLK1PLK2PLK3BRD4BRDT | |
| SCHEMBL1675828 | 0.86 | PLK1 (0.51) | PLK1PLK2PLK3BRD4BRDT | |
| SCHEMBL4106903 | 0.85 | PLK1 (0.41) | PLK1BRD4BRDTTTKPIP4K2A | |
| SCHEMBL25034678 | 0.84 | PLK1 (0.44) | PLK1PLK2PLK3BRD4BRDT | |
| SCHEMBL1675801 | 0.84 | PLK1 (0.44) | PLK1PLK2PLK3BRD4BRDT | |
| SCHEMBL2299825 | 0.84 | PLK1 (0.41) | PLK1PLK2PLK3BRD4BRDT | |
| SCHEMBL1675719 | 0.83 | PLK1 (0.43) | PLK1BRD4BRDTTTKPIP4K2A | |
| SCHEMBL1202616 | 0.83 | PLK1 (0.41) | PLK1BRD4BRDTTTKPIP4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291938-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
| US-20090291938-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
| US-20090291938-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
| WO-2009067547-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | WO | disclosed |
| WO-2009067547-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291938-A1 | POLO-LIKE KINASE INHIBITORS | PLK1, PLK2, POLK | PLK1 1/4885PLK2 2/4885PLK3 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.